Wall Street analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will post earnings of ($1.06) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.13) to ($0.88). Audentes Therapeutics reported earnings per share of ($0.84) during the same quarter last year, which suggests a negative year over year growth rate of 26.2%. The firm is expected to report its next quarterly earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Audentes Therapeutics will report full-year earnings of ($4.29) per share for the current year, with EPS estimates ranging from ($4.63) to ($3.97). For the next financial year, analysts forecast that the firm will post earnings of ($4.56) per share, with EPS estimates ranging from ($5.78) to ($3.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same quarter last year, the company posted ($0.97) earnings per share.

Several brokerages have commented on BOLD. Robert W. Baird began coverage on shares of Audentes Therapeutics in a research report on Wednesday, October 2nd. They issued an “underperform” rating and a $10.00 price target for the company. William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. BidaskClub cut shares of Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of Audentes Therapeutics in a research report on Friday. Finally, Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research report on Tuesday, October 8th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $40.76.

BOLD stock traded up $1.98 during midday trading on Friday, hitting $29.06. The company’s stock had a trading volume of 22,965 shares, compared to its average volume of 334,950. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $41.65. The firm has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.77. The firm has a 50-day simple moving average of $28.23 and a 200-day simple moving average of $34.39.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 20,000 shares of Audentes Therapeutics stock in a transaction on Monday, August 12th. The shares were sold at an average price of $34.04, for a total value of $680,800.00. Following the transaction, the chief executive officer now directly owns 135,368 shares in the company, valued at $4,607,926.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dupont Capital Management Corp acquired a new stake in Audentes Therapeutics during the 2nd quarter valued at $745,000. Prudential Financial Inc. lifted its position in Audentes Therapeutics by 272.3% in the 2nd quarter. Prudential Financial Inc. now owns 78,218 shares of the biotechnology company’s stock valued at $2,961,000 after purchasing an additional 57,210 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Audentes Therapeutics in the 2nd quarter valued at about $669,000. Voloridge Investment Management LLC acquired a new position in Audentes Therapeutics during the 2nd quarter valued at about $993,000. Finally, Global Endowment Management LP boosted its holdings in shares of Audentes Therapeutics by 14.9% in the second quarter. Global Endowment Management LP now owns 449,965 shares of the biotechnology company’s stock worth $17,036,000 after buying an additional 58,384 shares during the period. 98.44% of the stock is owned by institutional investors and hedge funds.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: What is a support level?

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.